Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBIT Margin: 2023-2025

Historic EBIT Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to 1,062.94%.

  • Inhibrx Biosciences' EBIT Margin was N/A to 1,062.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 1,728.54%, marking a year-over-year change of. This contributed to the annual value of -165,724.00% for FY2024, which is 15354506.00% down from last year.
  • Per Inhibrx Biosciences' latest filing, its EBIT Margin stood at 1,062.94% for Q3 2025, which was up 21.90% from 871.98% recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year EBIT Margin high stood at 3,001.27% for Q2 2024, and its period low was -257,447.06% during Q2 2023.
  • Its 3-year average for EBIT Margin is -38,205.41%, with a median of 871.98% in 2025.
  • Over the last 5 years, Inhibrx Biosciences' EBIT Margin had its largest YoY gain of 26,044,833bps in 2024, and its largest YoY loss of 4,452,476bps in 2024.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' EBIT Margin stood at -5,403.24% in 2023, then slumped by 4,452,476bps to -49,928.00% in 2024, then slumped by 212,928bps to 1,062.94% in 2025.
  • Its EBIT Margin was 1,062.94% in Q3 2025, compared to 871.98% in Q2 2025 and 1,595.43% in Q1 2025.